Related Experiment Video

Updated: Dec 17, 2025

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

2.8K

Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia

Yu-Chin Chen, Wei-Yun Hsu, Tu-Hsuan Chang

    Emerging Infectious Diseases
    |June 23, 2020
    PubMed

    Insights

    Macrolide-resistant Mycoplasma pneumoniae (MRMP) infections do not worsen clinical severity but prolong fever and hospital stays. This resistance poses diagnostic and treatment challenges, necessitating better tools and guidelines.

    Area of Science:

    • Infectious Diseases
    • Microbiology
    • Clinical Medicine

    Background:

    • High prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) reported in Asia.
    • Increasing macrolide resistance impacts M. pneumoniae treatment efficacy.
    • Understanding resistance effects is crucial for clinical management.

    Purpose of the Study:

    • To investigate the impact of macrolide resistance on M. pneumoniae infection manifestations.
    • To evaluate the effect of MRMP on clinical judgment and treatment outcomes.
    • To compare clinical severity between MRMP and macrolide-sensitive M. pneumoniae (MSMP) infections.

    Main Methods:

    • Systematic review and meta-analysis of M. pneumoniae infections.
    • Pooled data analysis comparing MRMP and MSMP patient outcomes.
    • Statistical analysis of clinical severity, febrile period, hospital stay, and treatment duration.

    Main Results:

    • No significant difference in overall clinical severity between MRMP and MSMP infections.
    • MRMP infections associated with longer febrile periods (1.71 days) and hospital stays (1.61 days).
    • Increased risk of prolonged fever (>48 hours) post-macrolide treatment (OR 21.24) and higher rates of second-line treatment (OR 4.42) in MRMP cases.

    Conclusions:

    • Macrolide resistance in M. pneumoniae presents diagnostic and therapeutic challenges.
    • Emergence of MRMP necessitates development of precise diagnostic tools.
    • Clearer treatment guidelines are required to manage MRMP infections effectively.
    Keywords:
    AsiaMycoplasma pneumoniaeantimicrobial resistancebacteriachildrenmacrolide resistancepneumonia

    More Related Videos

    Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

    Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

    Published on: February 23, 2014

    15.4K
    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

    A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

    Published on: January 2, 2017

    15.0K

    Related Concept Videos

    Pneumonia I: Introduction01:30

    Pneumonia I: Introduction

    Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
    Risk Factors
    Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
    620
    Pneumonia V: Nursing management and Prevention01:30

    Pneumonia V: Nursing management and Prevention

    Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
    The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
    Enhance airway patency
    Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
    3.2K
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    655
    Pneumonia II: Pathophysiology01:29

    Pneumonia II: Pathophysiology

    The pathophysiology of pneumonia involves the following steps:
    2.3K
    Pneumonia III: Complications and Assessment01:30

    Pneumonia III: Complications and Assessment

    Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
    688
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    141